TARSUS PHARMACEUTICALS, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
TARSUS PHARMACEUTICALS, INC. (TARS) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$585.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2024-05-08
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2024-03-31 was -$585.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-12-31 was $420.00K, a 624.14% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-09-30 was -$111.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-06-30 was $15.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $259.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$268.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2021 was -$591.00K.
- TARSUS PHARMACEUTICALS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2020 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$585.00K 10-Q · filed 2024-05-08 | -$165.00K derived: sum of 2 quarters · filed 2024-05-08 | -$276.00K derived: sum of 3 quarters · filed 2024-05-08 | -$261.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | $420.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $309.00K derived: sum of 2 quarters · filed 2024-02-27 | $324.00K derived: sum of 3 quarters · filed 2024-02-27 | $259.00K 10-K · filed 2024-02-27 |
| 2023-09-30 | -$111.00K 10-Q · filed 2023-11-09 | -$96.00K derived: sum of 2 quarters · filed 2023-11-09 | -$161.00K 10-Q · filed 2023-11-09 | -$103.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-06-30 | $15.00K 10-Q · filed 2023-08-10 | -$50.00K 10-Q · filed 2023-08-10 | $8.00K derived: sum of 3 quarters · filed 2024-05-08 | -$5.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-03-31 | -$65.00K 10-Q · filed 2024-05-08 | -$7.00K derived: sum of 2 quarters · filed 2024-05-08 | -$20.00K derived: sum of 3 quarters · filed 2024-05-08 | -$141.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $45.00K derived: sum of 2 quarters · filed 2024-02-27 | -$76.00K derived: sum of 3 quarters · filed 2024-02-27 | -$268.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | -$13.00K 10-Q · filed 2023-11-09 | -$134.00K derived: sum of 2 quarters · filed 2023-11-09 | -$326.00K 10-Q · filed 2023-11-09 | -$917.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$121.00K 10-Q · filed 2023-08-10 | -$313.00K 10-Q · filed 2023-08-10 | -$904.00K derived: sum of 3 quarters · filed 2023-08-10 | -$904.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$192.00K 10-Q · filed 2023-05-09 | -$783.00K derived: sum of 2 quarters · filed 2023-05-09 | -$783.00K derived: sum of 3 quarters · filed 2023-05-09 | -$783.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$591.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$591.00K derived: sum of 2 quarters · filed 2023-03-17 | -$591.00K derived: sum of 3 quarters · filed 2023-03-17 | -$591.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |